0000912282-15-000317.txt : 20150903 0000912282-15-000317.hdr.sgml : 20150903 20150902212119 ACCESSION NUMBER: 0000912282-15-000317 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150902 FILED AS OF DATE: 20150903 DATE AS OF CHANGE: 20150902 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aptose Biosciences Inc. CENTRAL INDEX KEY: 0000882361 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32001 FILM NUMBER: 151090601 BUSINESS ADDRESS: STREET 1: 5955 AIRPORT ROAD, SUITE 228 STREET 2: . CITY: MISSISSAUGA STATE: A6 ZIP: L4V 1R9 BUSINESS PHONE: 647-479-9828 MAIL ADDRESS: STREET 1: 5955 AIRPORT ROAD, SUITE 228 CITY: MISSISSAUGA STATE: A6 ZIP: L4V 1R9 FORMER COMPANY: FORMER CONFORMED NAME: Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) DATE OF NAME CHANGE: 20140905 FORMER COMPANY: FORMER CONFORMED NAME: LORUS THERAPEUTICS INC DATE OF NAME CHANGE: 19990308 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC PHARMA INC DATE OF NAME CHANGE: 19970113 6-K 1 aptose6k_090215.htm aptose6k_090215.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
___________________
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of September 2015
 
Commission File Number: 001-32001
 
___________________
 
Aptose Biosciences Inc.
(Translation of registrant's name into English)
 
5955 Airport Road, Suite 228
Mississauga, Ontario  L4V 1R9
Canada
 (Address of principal executive offices)
___________________
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-FR £                                           Form 40-F £
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)  £
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)  £
 
 


 
 
 

INCORPORATION BY REFERENCE

Exhibits 99.1 and 99.2 to the Report of Foreign Issuer on Form 6-K of Aptose Biosciences Inc. (the “Registrant”) containing interim financial statements and management’s discussion and analysis for the quarter ended March 31, 2015, furnished to the SEC on May 6, 2015, are each hereby incorporated by reference into the registration statement on Form F-3 of the Registrant (File No. 333-200660) and the prospectus, as supplemented by the prospectus supplement dated April 2, 2015, forming a part thereof.

Exhibits 99.1 and 99.2 to the Report of Foreign Issuer on Form 6-K of the Registrant furnished to the SEC on August 5, 2015, are each hereby incorporated by reference into the registration statement on Form F-3 of the Registrant (File No. 333-200660) and the prospectus forming a part thereof.




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


  Aptose Biosciences Inc.  
     
       
Date: September 3, 2015
By:
/s/  Gregory Chow  
  Name: Gregory Chow  
  Title: Senior Vice President and Chief Financial Officer